1. Home
  2. NUVB vs HAFC Comparison

NUVB vs HAFC Comparison

Compare NUVB & HAFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVB
  • HAFC
  • Stock Information
  • Founded
  • NUVB 2018
  • HAFC 1982
  • Country
  • NUVB United States
  • HAFC United States
  • Employees
  • NUVB N/A
  • HAFC N/A
  • Industry
  • NUVB Biotechnology: Pharmaceutical Preparations
  • HAFC Major Banks
  • Sector
  • NUVB Health Care
  • HAFC Finance
  • Exchange
  • NUVB Nasdaq
  • HAFC Nasdaq
  • Market Cap
  • NUVB 1.1B
  • HAFC 748.3M
  • IPO Year
  • NUVB N/A
  • HAFC 1996
  • Fundamental
  • Price
  • NUVB $3.26
  • HAFC $24.52
  • Analyst Decision
  • NUVB Strong Buy
  • HAFC Buy
  • Analyst Count
  • NUVB 6
  • HAFC 6
  • Target Price
  • NUVB $8.17
  • HAFC $26.00
  • AVG Volume (30 Days)
  • NUVB 6.7M
  • HAFC 143.5K
  • Earning Date
  • NUVB 11-05-2025
  • HAFC 10-21-2025
  • Dividend Yield
  • NUVB N/A
  • HAFC 4.34%
  • EPS Growth
  • NUVB N/A
  • HAFC N/A
  • EPS
  • NUVB N/A
  • HAFC 2.16
  • Revenue
  • NUVB $14,355,000.00
  • HAFC $233,739,000.00
  • Revenue This Year
  • NUVB $332.80
  • HAFC $17.13
  • Revenue Next Year
  • NUVB $360.12
  • HAFC $7.95
  • P/E Ratio
  • NUVB N/A
  • HAFC $11.52
  • Revenue Growth
  • NUVB 900.35
  • HAFC N/A
  • 52 Week Low
  • NUVB $1.54
  • HAFC $17.93
  • 52 Week High
  • NUVB $4.09
  • HAFC $27.59
  • Technical
  • Relative Strength Index (RSI)
  • NUVB 53.12
  • HAFC 48.25
  • Support Level
  • NUVB N/A
  • HAFC $24.47
  • Resistance Level
  • NUVB $3.44
  • HAFC $25.27
  • Average True Range (ATR)
  • NUVB 0.26
  • HAFC 0.47
  • MACD
  • NUVB -0.14
  • HAFC -0.06
  • Stochastic Oscillator
  • NUVB 79.58
  • HAFC 12.36

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

About HAFC Hanmi Financial Corporation

Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.

Share on Social Networks: